- Previous Close
72.88 - Open
78.25 - Bid 60.60 x 100
- Ask 63.27 x 800
- Day's Range
62.80 - 79.10 - 52 Week Range
9.34 - 99.41 - Volume
29,165,082 - Avg. Volume
3,302,948 - Market Cap (intraday)
7.036B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.94 - Earnings Date Oct 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
113.91
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
www.vikingtherapeutics.com30
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: VKTX
View More
Related Videos: VKTX
Performance Overview: VKTX
Trailing total returns as of 2024-11-04, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VKTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VKTX
View MoreValuation Measures
Market Cap
8.12B
Enterprise Value
7.19B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.68%
Return on Equity (ttm)
-15.50%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-99.15M
Diluted EPS (ttm)
-0.94
Balance Sheet and Cash Flow
Total Cash (mrq)
930.44M
Total Debt/Equity (mrq)
0.14%
Levered Free Cash Flow (ttm)
-44.29M